Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Adverse reactions to weight-loss jabs are set to soar by more than 350% in a single year, according to the latest data.

CEO Erez Israeli has projected double-digit growth for FY26, primarily on the back of semaglutide launches and pipeline ...

Bad reactions to popular weight-loss drugs, including Ozempic and Wegovy, are on track to soar by more than 350 per cent ...

A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...

The biosimilars segment, too, will see fresh launches including Bevacizumab in the US, and Semaglutide filings across developed and emerging markets, including India by calendar 2026.

It changed the way we diet, but now Weight Watchers’ fortunes seem to be fading. Katie Rosseinsky explores how the Ozempic ...

Avery is known for songs such as 'Go Screw Yourself (GSY) and 'Meant to Live', but the artist took to social media earlier ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Ozempic, Wegovy and Mounjaro can still be expensive, but pharmacy-produced GLP-1 compounds are becoming much more affordable.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal ...